INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Phase: Phase III clinical trials

Principal Investigator: Dott.ssa Fumagalli Elena

Main Facility: Oncologia Medica 2

Drug: Velzatinib (GSK6042981) versus Imatinib

Pathologies:

ClinicalTrials.gov: Read the details about clinical trials

This is a phase 3 clinical trial to evaluate the efficacy of Velzatinib (GSK6042981) compared to Imatinib in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have not previously been treated. 

GISTs are the most common type of mesenchymal tumors in the gastrointestinal tract, usually driven by activating mutations in KIT (~80%) or PDGFRA (~10%). First-line therapy with imatinib provides benefit in most patients, but resistance frequently develops, often due to secondary KIT mutations in exons 13, 14, 17, or 18.

Velzatinib is a highly selective oral KIT inhibitor with broad activity against both primary activating mutations (exons 9 and 11) and clinically relevant secondary resistance mutations (exons 13 and 17). By targeting these pathways, Velzatinib aims to inhibit tumor growth and improve clinical outcomes compared to currently approved first-line therapies.

Participants will receive either Velzatinib (Arm A) or Imatinib (Arm B). Treatment will continue until disease progression, intolerable toxicity, or other protocol-defined discontinuation criteria. Participants will be stratified by mutation type (KIT exon 11 vs KIT exon 9 vs other).

The main goal of the study is to see if Velzatinib can help patients live longer without their tumor getting worse, compared to Imatinib. This will be measured using scans reviewed by a team of experts who do not know which treatment each patient is receiving, to ensure fair and accurate results.

The study will also look at other important outcomes, such as how many patients have their tumors shrink, how long these responses last, how quickly the treatment works, and how well patients tolerate the medicine.

Participants will have regular check-ups and scans to monitor the effect of the treatment and watch for any side effects. An independent team of doctors and specialists will carefully oversee the study to ensure participants’ safety and that all results are reliable.

Last update: 10/11/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe